Brodalumab, an anti–interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study

OBJECTIVE: To evaluate the long-term efficacy and safety of brodalumab, a fully human anti–interleukin-17 receptor A monoclonal antibody, in patients with axial spondyloarthritis (axSpA). METHODS: Patients receiving subcutaneous brodalumab 210 mg during the 16-week double-blind period of this multic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tae-Hwan, Kishimoto, Mitsumasa, Wei, James Cheng-Chung, Jeong, Haeyoun, Nozaki, Akiyo, Kobayashi, Shigeto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152297/
https://www.ncbi.nlm.nih.gov/pubmed/36130275
http://dx.doi.org/10.1093/rheumatology/keac522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152297/
https://www.ncbi.nlm.nih.gov/pubmed/36130275
http://dx.doi.org/10.1093/rheumatology/keac522

Ejemplares similares